Effect of long-term treatment with Kanefron® H on the risk factors of the urinary system, associated with idiopathic calcium urolithiasis

Unlike many other forms of inflammatory arthritis, the crystal arthropathies are routinely diagnosed and managed in primary care. Gout, in particular, is relatively commonplace and rates of other types of crystal-related arthritis are predicted to increase. These are, therefore, conditions that GPs and trainees will regularly encounter during routine practice. While the clinical features and pathophysiology of gout and pseudo-gout are well described, the long-term treatment goals and options of management are often less well understood, and opportunities to assess for associated co-morbidities can easily be missed. GPs can be central in optimising management by promptly and appropriately addressing acute symptoms, preventing recurrent attacks, minimising disability and work absences, reducing cardiovascular risk factors, improving general health and enhancing quality of life.

Download Full-text

709 LONG-TERM TREATMENT WITH LAMIVUDINE UP TO TEN YEARS: PREDICTIVE VALUE OF HOST AND VIRUS RELATED RISK FACTORS FOR THE DEVELOPMENT OF HBV RESISTANCE

Journal of Hepatology ◽

10.1016/s0168-8278(08)60711-4 ◽

2008 ◽

Vol 48 ◽

pp. S264-S265 ◽

Cited By ~ 1

Author(s):

F. van Bömmel ◽

A. Brodzinski ◽

U. Mihm ◽

M.C. Jung ◽

C. Sarrazin ◽

...

Keyword(s):

Risk Factors ◽

Predictive Value ◽

Term Treatment ◽

Related Risk ◽

Long Term Treatment

Download Full-text

Tumor-necrosis Factor Inhibitors Improve Aortic Stiffness in Patients With Longstanding Rheumatoid Arthritis

10.21203/rs.3.rs-126056/v1 ◽

2020 ◽

Author(s):

Alessandro Giollo ◽

Giovanni Cioffi ◽

Federica Ognibeni ◽

Giovanni Orsolini ◽

Andrea Dalbeni ◽

...

Keyword(s):

Risk Factors ◽

Blood Pressure ◽

Aortic Stiffness ◽

Term Treatment ◽

Cvd Risk Factors ◽

Cvd Risk ◽

Long Term Treatment ◽

Necrosis Factor

Abstract Background. Major cardiovascular disease (CVD) benefits of disease-modifying anti-rheumatic drugs (DMARDs) therapy occur in early RA patients with treat-to-target strategy. However, it is unknown whether long-term DMARDs treatment in established RA could be useful to improve CVD risk profile.Methods. Ultrasound aortic stiffness index (AoSI) has to be considered a proxy outcome measure in established RA patients. We measured AoSI in a group of RA patients on long-term treatment with tumour necrosis factor inhibitors (TNFi) or conventional synthetic DMARDs (csDMARDs). Eligible participants were assessed at baseline and after 12 months; changes in serum lipids, glucose and arterial blood pressure were assessed. All patients were on stable medications during the entire follow-up. Results. We included 107 (64 TNFi and 43 csDMARDs) RA patients. Most patients (74%) were in remission or low disease activity and had some CVD risk factors (45.8% hypertension, 59.8% dyslipidemia, 45.3% smoking). The two groups did not differ significantly for baseline AoSI (5.95±3.73% vs 6.08±4.20%, p=0.867). Follow-up AoSI was significantly increased from baseline in the csDMARDs group (+1.00%; p<0.0001) but not in the TNFi group (+0.15%, p=0.477). Patients on TNFi had significantly lower follow-up AoSI from baseline than the csDMARD group (-1.02%, p<0.001; ANCOVA corrected for baseline AoSI, age and systolic blood pressure). Furthermore, follow-up AoSI was significantly lower in TNFi users with 1-2 or >2 CVD risk factors than in those without. Conclusion. Long-term treatment with TNFi was associated with reduced aortic stiffness in patients with established RA and several CVD risk factors.

Download Full-text

Usefulness of Nonvalved Spacers for Administration of Inhaled Steroids in Young Children with Recurrent Wheezing and Risk Factors for Asthma

Canadian Respiratory Journal ◽

10.1155/2018/3095647 ◽

2018 ◽

Vol 2018 ◽

pp. 1-5

Author(s):

Carlos Kofman ◽

Alejandro Teper

Keyword(s):

Risk Factors ◽

Fluticasone Propionate ◽

Young Children ◽

Respiratory Symptoms ◽

Term Treatment ◽

Recurrent Wheezing ◽

Inhaled Steroids ◽

Long Term Treatment ◽

Metered Dose

Background. In vitro and scintigraphic studies have suggested that effectiveness of metered-dose inhalers (MDI) with nonvalved spacers (NVS) is similar to that of MDI with valved holding chambers (VHC). Nevertheless, there are no clinical studies that compare these techniques in long-term treatment with inhaled steroids in young children with recurrent wheezing and risk factors for asthma. Objective. To compare the efficacy of a long-term treatment with Fluticasone Propionate administered by an MDI through both type of spacers, with and without valves, in young children with recurrent wheezing and risk factors for asthma. Patients and Methods. Outpatient children (6 to 20 months old) with recurrent wheezing and risk factors for asthma were randomized to receive a 6-month treatment with metered-dose inhaler (MDI) of Fluticasone Propionate 125 mcg BID through an NVS or through a VHC. Parents recorded daily their child’s respiratory symptoms and rescue medication use. Results. 46 patients of 13.4 ± 5 months old were studied. During the study period, the NVS group (n=25) experienced 3.9 ± 2.4 obstructive exacerbations, and the VHC group (n=21) had 2.6 ± 1.6 (p=0.031). The NVS group had 17.4 ± 14% of days with respiratory symptoms, and the VHC group had 9.7 ± 7% (p=0.019). The NVS group spent 29.8 ± 22 days on albuterol while the VHC group spent 17.9 ± 11 days (p=0.022). Conclusion. Long-term treatment with inhaled steroids administered by MDI and NVS is less effective than such treatment by MDI and VHC in infants with recurrent wheezing and risk factors for asthma.

Download Full-text

Plasma ionized calcium and cardiovascular risk factors in mild primary hyperparathyroidism: effects of long-term treatment with active vitamin D (Alphacalcidol)

Journal of Internal Medicine ◽

10.1111/j.1365-2796.1992.tb00955.x ◽

1992 ◽

Vol 231 (4) ◽

pp. 427-432 ◽

Cited By ~ 11

Author(s):

L. LIND ◽

B. WENGLE ◽

H. LITHELL ◽

S. LJUNGHALL

Keyword(s):

Risk Factors ◽

Vitamin D ◽

Cardiovascular Risk ◽

Primary Hyperparathyroidism ◽

Cardiovascular Risk Factors ◽

Term Treatment ◽

Active Vitamin ◽

Long Term Treatment ◽

Mild Primary Hyperparathyroidism

Download Full-text

Risk factors for long-term treatment of whiplash injury in Japan: analysis of 400 cases

Archives of Orthopaedic and Trauma Surgery ◽

10.1007/s004020100284 ◽

2001 ◽

Vol 121 (9) ◽

pp. 490-493 ◽

Cited By ~ 7

Author(s):

A. Hijioka ◽

K. Narusawa ◽

T. Nakamura

Keyword(s):

Risk Factors ◽

Whiplash Injury ◽

Term Treatment ◽

Long Term Treatment

Download Full-text

Long-term effects of ibrutinib on blood pressure in patients with chronic lymphocytic leukemia (CLL).

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.e19009 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. e19009-e19009 ◽

Cited By ~ 1

Author(s):

Jade Jones ◽

Binsah George ◽

Christine B Peterson ◽

Jan Andreas Burger ◽

Nitin Jain ◽

...

Keyword(s):

Risk Factors ◽

Blood Pressure ◽

Tobacco Use ◽

Term Treatment ◽

Lymphocytic Leukemia ◽

High Rate ◽

Long Term Effects ◽

Obstructive Sleep ◽

Long Term Treatment

e19009 Background: Ibrutinb is approved for treatment of CLL. Hypertension (HTN) has been reported as a side effect of ibrutinib in 1-23% of patients. We previously reported HTN in CLL patients after 6 months of treatment with ibrutinib. In this study we describe the effects of long-term treatment with ibrutinib on blood pressure (BP). Methods: We performed a retrospective study, evaluating 150 CLL patients on ibrutinib-based clinical trials from 2010 to 2015. Patient demographics, co-morbidities, tobacco use, anti-HTN therapy were recorded. BP was evaluated at baseline and sequentially for up to 5 yrs. New onset HTN was defined as systolic BP (SBP) of ≥ 130 mmHg and/or diastolic BP (DBP) ≥ 80 on two separate visits with no prior HTN or anti-HTN therapy. An increase in baseline SBP by ≥10 and/or increase in DBP by ≥10 was considered significant regardless of the absolute BP. Univariate logistic regression analysis was performed to assess relationship of HTN risk factors and new HTN. Results: Patients’ median age was 65 yrs (68% male and 88% white). Median follow-up was 3 yrs. Pre-existing HTN was present in 44% of patients, 40% were on anti-HTN therapy prior to ibrutinib. New HTN developed in 65% of patients without prior diagnosis of HTN; 32 % of patients were started on anti-HTN therapy or received additional anti-HTN therapy. Of the patients who experienced an increase in BP, 33% experienced isolated systolic HTN. Median SBP was 130 at baseline, 132 at 1mo, 137 at 3mo, 135 at 6mo, 139 at 12mo, 138 at 3yrs, 144 at 5yrs (mean increase in SBP: 7.2, P < 0.001). In patients whose SBP was < 130 at baseline the median SBP was 119 at baseline, 122 at 1mo, 134 at 3mo, 130 at 6mo, 134 at 12mo, 135 at 3yrs and 141 at 5yrs (mean increase in SBP: 15.7, p < 0.001). 74% of patients experienced and increase in SBP ≥10. New HTN on ibrutinib was not associated with: tobacco use, obesity, chronic kidney disease or obstructive sleep apnea (p > 0.05). Conclusions: In this study we demonstrated a high rate of new HTN in patients on prolonged ibrutinib treatment. HTN in these patients is persistent, linear and independent of other risk factors. The increase in BP remained despite initiation of anti-HTN therapy. Additional studies are ongoing to define cardiovascular and renal complications associated with HTN in these patients.

Download Full-text